Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 75Leukemia, Myeloid, Acute 68Leukemia, Myelogenous, Chronic, BCR-ABL Positive 35Myeloproliferative Disorders 33Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Lymphoma, Non-Hodgkin 21Primary Myelofibrosis 17Leukemia, Myelomonocytic, Chronic 17Leukemia 14Hodgkin Disease 14Myelodysplastic-Myeloproliferative Diseases 11Polycythemia Vera 10Leukemia, Biphenotypic, Acute 10Histiocytosis, Langerhans-Cell 10Anemia, Refractory, with Excess of Blasts 10Sarcoma 9Neuroblastoma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Glioma 9Wilms Tumor 8Rhabdoid Tumor 8Neuroectodermal Tumors, Primitive, Peripheral 8Multiple Myeloma 8Medulloblastoma 8Hepatoblastoma 8Ependymoma 8Blastic Plasmacytoid Dendritic Cell Neoplasm 8Blast Crisis 8Thrombocythemia, Essential 7Rhabdomyosarcoma 7

Interventions

luspatercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
beta-Thalassemia × Myeloid × 30 days × Clear all
NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡